Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | GRK2 | P25098 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674759 | 1.00 | CA2 (0.62) | CA2CAMK2AAKR1B1LMNAGAA | |
| Hydrochloric Acid SCHEMBL27999838 | 0.98 | CA2 (0.60) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL5924483 | 0.88 | SRD5A2 (0.62) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL69614 | 0.87 | CA2 (0.79) | CA2CAMK2AAKR1B1LMNAGAA | |
| Hydrochloric Acid SCHEMBL25180348 | 0.84 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAGAA | |
| Hydrochloric Acid SCHEMBL6765874 | 0.84 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL2642144 | 0.82 | CA2 (0.65) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL27740202 | 0.80 | CA2 (0.62) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL18427891 | 0.79 | LMNA (0.86) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL68027 | 0.79 | LMNA (0.86) | CA2CAMK2AAKR1B1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | C-BIOMEX CO., LTD. (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2025023747-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | (주)씨바이오멕스 | 2025-01-30 | — | — | WO | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2024-02-15 | — | — | US | claimed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | claimed |
| WO-2023137518-A1 | PLATINUM COMPLEXES | Western Sydney University (AU) | 2023-07-27 | — | — | WO | claimed |
| US-20230165979-A1 | COPPER-CONTAINING THERAGNOSTIC COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2023-06-01 | — | — | US | claimed |
| CN-115989042-A | Copper-containing theranostic compounds and methods of use | 康奈尔大学 | 2023-04-18 | — | — | CN | claimed |
| EP-4146236-A1 | COPPER-CONTAINING THERAGNOSTIC COMPOUNDS AND METHODS OF USE | Cornell University (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2021225760-A1 | COPPER-CONTAINING THERAGNOSTIC COMPOUNDS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2021-11-11 | — | — | WO | claimed |
| US-5710178-A | ARYL- AND ARYLOXYALKANOIC ACIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-20 | — | — | US | claimed |
| US-5708025-A | BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-13 | — | — | US | claimed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | claimed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | claimed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | claimed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | claimed |
| EP-0460111-B1 | PREPARATION OF 4-SUBSTITUTED ARYL OLEFINS | EASTMAN KODAK CO (US) | 1993-12-08 | — | — | EP | claimed |
| US-4252719-A | REMOVAL OF A TERTIARY HYDROGEN FROM A 5-A-STEROID BY CHLORINATING THE STEROID BEING FIRST ESTERIFIED BY AN IODOARYL-CONTAINING ESTERIFICATION AGENT | RESEARCH CORPORATION (US) | 1981-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | CA2 2692/4885CAMK2A 1586/4885AKR1B1 535/4885 |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | CA2 2692/4885CAMK2A 1586/4885AKR1B1 535/4885 |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | CA5A, CA1, CA9 | CA2 6/4885CAMK2A 1077/4885AKR1B1 964/4885 |
| US-20230165979-A1 | COPPER-CONTAINING THERAGNOSTIC COMPOSITIONS AND METHODS OF USE | SHBG, FABP6, SERPINA6 | CA2 255/4885CAMK2A 1547/4885AKR1B1 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.